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Matrix stiffness induces epithelial–mesenchymal transition
and promotes chemoresistance in pancreatic cancer cells
AJ Rice1, E Cortes1, D Lachowski1, BCH Cheung1, SA Karim2, JP Morton2 and A del Río Hernández1
Increased matrix rigidity associated with the ﬁbrotic reaction is documented to stimulate intracellular signalling pathways that
promote cancer cell survival and tumour growth. Pancreatic cancer is one of the stiffest of all human solid carcinomas and is
characterised by a remarkable desmoplastic reaction. Here we use mouse models, genetically engineered to recapitulate human
pancreatic cancer, and several pancreatic cancer cell lines as a model to investigate the effect of matrix stiffness in epithelial–
mesenchymal transition (EMT) and resistance to chemotherapeutics. We found that recapitulation of the ﬁbrotic rigidities found in
pancreatic cancer tissues promote elements of EMT, including increases in vimentin expression, decreases in E-cadherin expression,
nuclear localisation of β-catenin, YAP and TAZ and changes in cell shape towards a mesenchymal phenotype. We also report that
stiffness induces chemoresistance to paclitaxel, but not to gemcitabine, both commonly used therapeutics, suggesting that
environmental rigidity underlies an aspect of chemoresistance.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth most lethal
cancer in the developed world, with 4200 000 deaths per year
across the world. Currently, the 5-year survival rate is o4%, and
the cancer responds very poorly to chemotherapeutic agents.1,2
PDAC tumours are usually detected at advanced stages due to
rapid progression, with limited symptoms at early stages, meaning
only 10% are operable.2 Tumours arise from ductal cells over an
extended period, gradually accumulating mutations, from healthy
pancreas to pancreatic intraepithelial neoplasia (PanIN), before full
development into PDAC.3
The PDAC stroma is highly ﬁbrotic due to desmoplasia, the
deposition of a dense and crosslinked extracellular matrix (ECM),
and is particularly pronounced in PDAC.4,5 Fibrosis is an
environmental property associated with risk of cancer develop-
ment in liver cirrhosis and breast.6 The stiffness associated with
desmoplasia can promote tumour malignancy across multiple
organs, as the rigid stroma forces a tensional homeostasis with
high levels of cell contractility to counteract the stiff environment,
inducing intracellular signalling and malignant transformation.7 In
breast cancer, tumorigenesis is associated with ECM stiffening and
collagen crosslinking, which promotes the formation of integrin-
containing focal adhesions at the cell membrane,8 leading to
intracellular signalling involving extracellular signal–regulated
kinase and ROCK-generated contractility, promoting a malignant
phenotype.7 Additionally, matrix stiffness has been seen in
hepatocellular carcinoma cells to regulate resistance to che-
motherapeutics, including paclitaxel.9
The epithelial–mesenchymal transition (EMT) is a process in
which cells become more motile through loss of cell–cell adhesion
and their apical–basal polarity. This process is suggested to be
vital for progression of PDAC,10 although controversial,11 as well as
chemoresistance.12 EMT is a multifaceted transition and is
characterised through changes in cell morphology and the
behaviour of many proteins, including vimentin, E-cadherin,
β-catenin,13 YAP and TAZ.14 Many elements of EMT have been
observed in pancreatic cancer, including elevated expression of
YAP and TAZ15 and increased nuclear YAP localisation and
activity.16 Stiffness is associated with EMT in other cancers, such
as in breast cancer, where a stiff ECM induces elements of EMT
through mechanotransduction.17 Mechanical activation of
β-catenin has been observed for in vivo mouse colon,18 and
vimentin organisation has been seen to be altered by the in vivo
mechanical environment.19 YAP and TAZ, transcription factors
known to be associated with EMT, have also emerged recently as
key players that control induction of fundamental cell processes in
response to ECM stiffness.20
Resistance to chemotherapeutic drugs has many suggested
causes, including cancer cells with intrinsic resistance mechan-
isms, as well as stromal cells maintaining a desmoplastic
microenvironment that promotes cancer cell resistance by
providing an environment that hampers drug delivery.21 EMT in
PDAC, as induced through Snail or Twist pathways, has been
suggested to be unnecessary for invasion and metastasis,
with knockout of either the Snail or Twist effectors not affecting
tumour dissemination but instead playing an important role in
chemoresistance to the antiproliferative agent gemcitabine.11
Most chemotherapies for pancreatic cancer are based on
gemcitabine.21 Loss of the EMT marker TAZ in breast cancer cells
impairs their chemoresistance,22,23 and TAZ is known to be
upregulated in pancreatic cancer cells.15
Owing to the highly ﬁbrotic nature of PDAC and its association
with poor survival, we investigate this form of cancer for
mechanical induction of a malignant phenotype. First, we
characterise the mechanics of healthy pancreas, PanIN and PDAC
tissues. We then show that recapitulation of the ﬁbrotic rigidities
can promote elements of EMT in pancreatic cancer cell lines,
including increases in vimentin expression, decreases in
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E-cadherin expression, nuclear localisation of β-catenin, YAP and
TAZ and changes in cell shape towards a mesenchymal
phenotype. This indicates not only the role of stiffness in induction
of the mesenchymal phenotype but also the plasticity and
non-discrete nature of the transition. We also report that stiffness
induces chemoresistance to paclitaxel, but not to gemcitabine,
suggesting that environmental rigidity underlies an aspect of
chemoresistance.
RESULTS
PDAC progression shows increased tissue tension and alignment
and thickening of collagen ﬁbres
To characterise in detail the changes that occur in the collagen
architecture and tissue mechanics in the pancreas during the
transition from healthy pancreas to premalignant lesions to
PDAC, we used pancreas from (i) C (Pdx1-Cre) mice for normal
pancreas,24 (ii) KC PanIN mice (Pdx1-Cre; LSL-KrasG12D/+) for
premalignant lesions and (iii) KPC mice (Pdx-1 Cre, LSL-KrasG12D/+,
LSL-Trp53R172H/+) for PDAC pancreas.25 PDX-Cre driver lines are used
in these mouse models to conditionally activate the target genes,
with the transcription factor PDX present in all pancreatic cells.26
Mutations in the tumour-suppressor gene p53 and activating
mutations in the Kras oncogene are commonly used to recapitulate
pancreatic cancer phenotypes in mouse models27 and are seen
frequently in human pancreatic cancers, with p53 mutations in 75%
and Kras mutations in 95% of cancer samples.28
The amount of collagen-I is known to be increased in the
ﬁbrotic stroma of PDAC compared with normal pancreas, and this
promotes cell survival and proliferation.16,29 Thick collagen ﬁbres
are indicative of poorly differentiated PDAC tumours and short
survival of patients.16 Using Sirius Red staining of 10 μm-thick
sections of tissue, we observe that ﬁbre thickness differs
signiﬁcantly from normal pancreas (2.8 μm) to the intermediate
PanIN stage (3.6 μm) and PDAC (3.7 μm) (Figure 1a). Fibre
thickness was calculated with the ImageJ plugin BoneJ.30 The
thickening of ﬁbres therefore occurs at an early stage of cancer
development before full progression to PDAC.
Alignment of collagen-I ﬁbres has been observed in PDAC
samples31 and is known to promote metastasis in breast cancer,
possibly by changing matrix stiffness and/or reducing spatial
impedance to enhance migration.32 The analysis technique used
here produces a two-dimensional Fourier transform of the original
image and performs radial summation (summing pixel intensities
along each radial angle) to assess the anisotropy of the Fourier
transform, which is related to the alignment of pixels in the
original image.33 Taking images across the entire section, collagen
ﬁbres appear to be loosely organised in the normal pancreas,
showing limited order and alignment, whereas ﬁbres in PDAC
appear to show high levels of organisation and alignment, in
agreement with previous studies.31 PanIN shows small regions
of alignment but is overall disorganised. Radial summation
alignment analysis33 has been used to quantify these changes
for 75 × 75 μm2 regions of interest, indicating signiﬁcant increases
in ﬁbre alignment during PDAC progression (Figure 1a). Estimation
of collagen organisation by Sirius Red alone does not comprehen-
sively detail ﬁbre organisation, as other weakly birefringent
materials such as keratin and ﬁbrin may also be stained and
ﬁbres parallel to the light transmission axis are not visualised
when linearly polarised light is used.34
Tissue stiffness is associated with tumour malignancy, and the
Young’s moduli of pancreatic tissue samples were assessed
through atomic force microscopy (AFM) (Figure 1b), indicating
an increase in stiffness between a PanIN and a PDAC mouse
model, at a micron scale.16 AFM here is used at a larger scale with
a bead of 70 μm diameter for direct comparison with the regions
of collagen ﬁbre analysis. This evaluation shows a heterogeneity in
tumour stiffness (Figure 1c), an observation previously seen
in breast cancer.35 Histograms showing the range of stiffnesses
show a skew to softer regions (o1 kPa) in all conditions, but
with progression from healthy pancreas to PanIN to PDAC, this
skew is less prevalent, demonstrating that stiffness increases
with ﬁbrosis and suggesting altered mechanotransduction.
Low stiffness regions are present in all samples, suggesting
that ECM remodelling during ﬁbrosis occurs at a local scale and
to speciﬁc elements of the tissue.
The mean values for Young’s modulus (Figure 1d(i)) differ
signiﬁcantly between normal and PanIN (Po0.0001) and between
normal and PDAC (P= 0.0423), though no signiﬁcant difference
is observed between PanIN and PDAC (P= 0.0751). A one-way
non-parametric analysis of variance determines that the medians
are signiﬁcantly different between conditions (Po0.0001).
Mechanosensitivity is likely dominated by the stiffer regions of
the tissue, and therefore the upper quartile measurements of the
data set are also compared (Figure 1d(ii)), showing a signiﬁcant
increase in Young’s modulus from healthy pancreas (1 kPa) to
PanIN (2 kPa) to PDAC (4 kPa). These upper quartile mean stiffness
values were taken forward into in vitro experiments.
Elements of EMT are induced in vitro in pancreatic cancer cells by
PDAC-relevant rigidities
Based on the in vivo stiffness variations observed with AFM,
pancreatic cancer cell lines were cultured on polyacrylamide gels
of tunable rigidity to observe molecular changes associated with
EMT. The stiffness values of 1, 4 and 25 kPa were created using
differing concentrations of acrylamide/bisacrylamide to represent
healthy pancreas, PDAC and an extreme stiffness, respectively.
Acrylamide/bisacrylamide ratios were used to produce gels of a
speciﬁc Young’s modulus and veriﬁed by AFM (Supplementary
Figure S1), before being coated with ﬁbronectin to produce the
same surface ligand proﬁle.
Three pancreatic cancer cell lines were used, originating from
different stages of cancer development. BxPC-3 cells represent a
highly epithelial phenotype, derived from a patient with no
observed metastases and show mutations in the gene for p53,36
and high expression of the marker E-cadherin, a protein involved in
cell–cell adhesion37 and associated with the epithelial phenotype.38
AsPC-1 cells represent an intermediate phenotype from a patient
with some metastasis36, show faster proliferation than BxPC-3 cells
and have mutations in the genes for Kras and p53.36 Suit2-007 cells
represent a highly mesenchymal phenotype, causing spontaneous
metastasis in nude mice xenografts.39 Characteristic mesenchymal
phenotypic markers are assessed to demonstrate EMT across the
cell population: increases in vimentin expression, decreases in
E-cadherin expression, increases in nuclear localisation of β-catenin,
and a more elongated cell shape.40
All cell lines, when grown on gels with a stiffness of 1, 4 and
25 kPa, showed increases in vimentin expression with gel rigidity,
as observed by immunoﬂuorescence (Figure 2a, Supplementary
Figure S2A), PCR (Figure 2d) and western blotting (Supplementary
Figure S3) were also used for BxPC-3 cells. With vimentin
immunoﬂuorescence intensity normalised to 1.0 for the 1 kPa
data set for each cell line, the highly epithelial cell line BxPC-3
showed high sensitivity to matrix rigidity with vimentin expression
increasing by a factor greater than that observed in the more
mesenchymal cell lines, AsPC-1 and Suit2-007 (Figures 2a and b).
Localisation of the cell adhesion-associated molecule β-catenin to
the nucleus is indicative of EMT and is here observed by
immunoﬂuorescence (Figures 2a and c) to become localised to
the nucleus with increasing stiffness in all cell lines, with the more
epithelial line BxPC-3 once again showing higher sensitivity to
stiffness-induced EMT than the mesenchymal Suit2-007 line.
Cell shape is observed to change with stiffness also, with the
parameter of cell roundness (calculated from the variance of the
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radii of the cell) decreasing with stiffness, with BxPC-3 showing
the highest sensitivity (Figure 2e).
The highly sensitive cell line BxPC-3 was also characterised
for E-cadherin expression, as well as the additional markers
of (i) loss of intracellular junctions and (ii) abundance of
cytoskeletal ﬁlaments, both of which have been previously
classiﬁed as minor criteria for EMT.13 E-cadherin, a marker for
the epithelial phenotype, is seen through immunoﬂuorescence
and PCR in BxPC-3 cells to decrease with increasing stiffness
(Figures 2a and d), showing loss of cell–cell adhesion. The
percentage of BxPC-3 cells that do not show clustering behaviour
increases with stiffness, denoting loss of cell–cell junctions
and subsequent individualisation (Supplementary Figure S2B),
though this measure is only a surrogate marker for changes in
cell adhesion.
Changes in extracellular stiffness are expected to induce
a tensional homeostasis in which the cytoskeleton is remodelled
and reinforced to match the force provided by the environment.
This is observed through increases in F-actin levels (Supple-
mentary Figure S2C). Phalloidin staining was used for F-actin
quantiﬁcation as this bicyclic heptapeptide binds speciﬁcally to
F-actin ﬁlaments without binding to the monomeric G-actin.41
F-actin intensity is used here as a surrogate marker for cell
contractility, and further experiments such as traction force
microscopy would be needed to document changes in cell force.
The plasticity of EMT is therefore revealed, as gradual increases
in stiffness can progressively promote mesenchymal behaviour
rather than just a binary switch between the epithelial and
mesenchymal phenotypes.
Matrix rigidity promotes YAP/TAZ nuclear localisation
YAP and TAZ are functionally redundant homologous transcrip-
tional activators that can promote oncogenic transformations,
such as EMT.42 YAP/TAZ is activated by dephosphorylation and in
this state can shuttle from the cytoplasm into the nucleus to bind
to transcription factors such as TEAD and promote gene
expression. Phosphorylation of YAP by LATS1/2 on Ser127 is
inhibitory and prevents nuclear localisation through cytoplasmic
sequestration by proteins, such as 14-3-3 and DVL.43 YAP and TAZ
nuclear localisation has been shown to be inﬂuenced by
mechanical forces,20 and their expression is increased in patients
with either PDAC or chronic pancreatitis.15,44
For the three different pancreatic cancer cell lines, both YAP and
TAZ localisation signiﬁcantly increase with gel rigidity, with the
highest mechanosensitivity in BxPC-3 cells, the most epithelial of
the cell lines (Figures 3a–c), showing the same trend as other
mesenchymal markers. YAP localisation reaches a maximum of
70–75%, whereas TAZ localisation is slightly higher at around 80%
for BxPC-3 and AsPC-1 cells, reaching an increased value of 90% in
the highly mesenchymal Suit2-007 cells. YAP and TAZ vary in
structure45 and these slight differences may underlie the minor
difference in localisation percentage as part of the stiffness
response. The expression of the YAP target genes CTGF and
ANKRD120 are seen to increase with stiffness for BxPC-3 cells
through PCR (Figure 3d), conﬁrming that YAP/TAZ activity is
affected by stiffness.
Though matrix stiffness can promote localisation of YAP and
TAZ, this phenotype is not dominant over known inhibitors of
YAP/TAZ localisation (Supplementary Figure S4). Adrenaline
stimulates G-protein-coupled receptor signalling, leading to
Figure 1. In vivo characterisation of extracellular changes during PDAC progression. (a) Sirius Red staining of 10 μm-thick sections of mouse
pancreatic tissue for normal pancreas, PanIN and PDAC. Fibre thickness is quantiﬁed through BoneJ analysis (normal, n= 41; PanIN, n= 48;
PDAC, n= 71) and alignment score through Radial Summation Alignment Analysis of 75 × 75 μm2 regions of interest (normal, n= 65; PanIN,
n= 45; PDAC, n= 52). Values represent mean± s.e.m. **Po0.01, ***Po0.0001. (b) Schematic diagram of AFM determination of Young’s
modulus of pancreatic tissue. A laser reﬂected off a cantilever is deﬂected by deformation of a cantilever with a 70 μm glass bead attached.
This produces a force curve that is ﬁtted to the Hertz model for a Young’s modulus value. (c) Histograms showing the range of local Young’s
modulus measurements across pancreatic tissue conditions: normal (n= 132), PanIN (n= 131), and PDAC (n= 175). (d) Bar graph from
histograms in panel (c), representing the whole data set (i) and the upper quartile (ii) data points from histograms in panel (c), representing
the maximum rigidities present in the tissue. Normal, n= 31; PanIN, n= 33; PDAC, n= 41. Values represent mean± s.e.m. *Po0.05, **Po0.001,
***Po0.0001 for unpaired Mann–Whitney test. †††Po0.0001 for Kruskal–Wallis test.
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phosphorylation and deactivation of YAP/TAZ,46 and 10 μM
adrenaline is observed here to inhibit YAP localisation even under
high stiffness conditions. Additionally, blebbistatin, which inhibits
actomyosin contraction and therefore prevents YAP/TAZ nuclear
localisation,47 is observed to inhibit YAP/TAZ localisation at a
concentration of 50 μM across the range of rigidities tested.
Matrix stiffness promotes chemoresistance to paclitaxel but not
gemcitabine
BxPC-3 cells show the highest sensitivity to matrix stiffness in
induction of EMT, and we used these cells to assess the role of
stiffness in inducing chemoresistance. Resistance to chemother-
apeutic drugs underlies the malignancy of PDAC, with EMT known
to induce a resistant phenotype.21 Multiple cytotoxic drugs are
used in PDAC chemotherapies, including gemcitabine21 and
paclitaxel.48 Gemcitabine is a nucleoside analogue used in
treatment of metastatic pancreatic cancer49 where it competes
against deoxycytidine triphosphate and cytidine triphosphate for
incorporation into DNA and RNA, respectively.50 In vivo EMT has
been observed to protect pancreatic cancer cells from the
antiproliferative effects of gemcitabine.11 Paclitaxel is a taxane,
which binds to, and stabilises, microtubules to suppress their
dynamics and subsequently inhibit mitosis51 and is used as a
treatment for metastatic pancreatic cancer in an albumin-bound
form.52 Treatment of patients with paclitaxel has been shown to
decrease tumour stiffness in vivo.53 Resistance to paclitaxel and
mesenchymal phenotype are uncorrelated among pancreatic cell
lines,54 though EMT is observed to promote paclitaxel resistance
for in vitro breast cancer cell lines.55
For rigidities of 1, 4 and 25 kPa, the response of BxPC-3 cells to
gemcitabine was unaffected by matrix rigidity (Figures 4a and b).
The IC50 values for 1, 4, and 25 kPa were 2, 4 and 2 μM,
respectively, and not signiﬁcantly different from each other
(P= 0.6, extra sum of squares F-test). Vimentin intensity under
control and 1 mM gemcitabine conditions was assessed
(Figure 4c), showing that the drug prevented the mesenchymal
phenotype from persisting which may underlie the similarity in
response of these cells under increasing rigidities. Moreover, both
YAP and TAZ localisation were observed to increase with an
increasing concentration of gemcitabine, showing 70–80%
localisation in all rigidities at a gemcitabine concentration of
1 mM (Figure 4d). This apparent selection for mesenchymal cells is
inconsistent with the observed alterations in vimentin, tentatively
suggesting an alternative process in which gemcitabine, by
preventing transcription through its nucleoside analogue activity,
deregulates the LATS1/2 feedback loop56 in which transcriptional
activation of LATS1/2 by YAP/TAZ is necessary. Further experi-
ments involving assessment of LATS1/2 activation are required to
evaluate this hypothesis.
In contrast, 4 and 25 kPa matrices are observed to
promote increased levels of chemoresistance of BxPC-3 cells to
paclitaxel when compared with the 1 kPa culture condition
(Figures 4e and f). IC50 values were calculated as the paclitaxel
concentration that produced 50% of the maximum inhibition
response, which was not 100% inhibition for any of the cell
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Figure 2. Role of matrix stiffness in EMT induction. (a) Vimentin, E-cadherin and β-catenin immunoﬂuorescence images of BxPC-3 cells on
matrices of varying stiffness. For β-catenin, main image shows merge of marker staining (green), top right inset is marker staining and bottom
left inset is phalloidin staining (red) of actin cytoskeleton to show cell shape and DAPI (blue). Scale bar= 25 μm. (b) Normalised vimentin
intensity (corrected cell total ﬂuorescence). For 1, 4 and 25 kPa, respectively, BxPC-3, n= 33, 39, 31; AsPC-1, n= 31, 35, 29; Suit2-007, n= 41, 33,
45. Values represent mean± s.e.m. **Po0.01, ***Po0.0001. (c) Nuclear localisation percentage for β-catenin and YAP. For 1, 4 and 25 kPa,
respectively, BxPC-3, n= 13, 9, 13; AsPC-1, n 10, 11, 7; Suit2-007, n= 11, 11, 12. Values represent mean± s.e.m. *Po0.05, **Po0.01.
(d) Expression of EMT markers vimentin and E-cadherin at the mRNA level. Values represent mean± s.e.m. For an unpaired t-test, *Po0.05.
N values for each protein at 1, 4 and 25 kPa, respectively, vimentin: 4, 6, 5; E-cadherin: 3, 6, 4. (e) Quantiﬁcation of roundness for cells grown on
matrices of varying rigidities. For 1, 4 and 25 kPa, respectively, BxPC-3, n= 13, 15, 15; AsPC-1, n= 19, 19, 15; Suit2-007, n= 17, 13, 13. Values
represent mean± s.e.m. *Po0.05, ***Po0.001.
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conditions. Cells on a 1 kPa gel show an IC50 value of 0.1 nM
(log IC50 =− 9.9), signiﬁcantly different (P= 0.0004) than the 0.7 nM
value (log IC50 =− 9.2) for the 4 kPa condition. Furthermore, the
25 kPa condition has a higher IC50 value of 1.4 nM (log IC50 =− 8.9).
The minimum level of cell viability achieved by paclitaxel exposure
is around 37% for 1 and 4 kPa conditions and signiﬁcantly higher
(Po0.0001) at 67% for the 25 kPa condition. The partial
mesenchymal phenotype therefore achieved at 4 kPa (Figure 2)
appears to be correlated with paclitaxel sensitivity, and this
chemoresistance is further potentiated at the 25 kPa condition.
Paclitaxel treatment of 1 μM is also observed to promote an
increase in the intensity of the mesenchymal marker vimentin
(Figure 4g) across all three rigidities, suggesting that the cells that
survive the inhibitory concentration of paclitaxel are cells with a
mesenchymal phenotype. It can therefore be speculated that the
mesenchymal phenotype, present in an increasing number of cells
with increasing stiffness, is conferring resistance to paclitaxel. In a
further difference to gemcitabine, YAP/TAZ levels do not change
with inhibitory concentrations of paclitaxel (Figure 4h), suggesting
that, for 1 and 4 kPa at least, drug-induced cell death does not
discriminate based on YAP/TAZ localisation.
DISCUSSION
In this study, we characterise the mechanical and structural
properties of PDAC tissues following development from a healthy
state and assess the role of the matrix rigidity component in
promoting the malignant phenotype of EMT and chemoresistance
in pancreatic cancer cells in vitro. Matrix rigidity is observed to be
able to promote progression from the epithelial towards the
mesenchymal phenotype in pancreatic cancer cell lines and allows
insight into the role of EMT in resistance to the chemotherapeutic
agents, gemcitabine and paclitaxel. These ﬁndings begin
to speciﬁcally examine the role of matrix stiffness in the
PDAC microenvironment in tumour malignancy and allude to an
in vivo environment in which multiple external components act
synergistically to induce malignant properties.
Development of PDAC from healthy pancreas involves many
changes in the ECM and its properties. These include increases in
tissue stiffness, as consistent with previous studies,16 as well as
alterations in ECM organisation comprising increases in alignment
and thickness of collagen-I ﬁbres. The region of interest sizes were
chosen to be large enough to capture the heterogeneous nature
of the tissue, yet localised enough to detect speciﬁc changes to
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Figure 3. Localisation of YAP/TAZ in response to matrix stiffness. (a) Changes in YAP and TAZ localisation to the nucleus in BxPC-3, AsPC-1 and
Suit2-007 cell lines, as shown by immunoﬂuorescence, with increasing matrix stiffness. For β-catenin, main image shows merge of marker
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the ECM. The use of non-subjective quantitative analysis tools for
speciﬁc quantiﬁcation of aspects of collagen organisation using
recently developed algorithms30,33 adds further characterisation of
the desmoplasia involved and removes the possibility of bias and
subjectivity in conclusions. This is particularly relevant considering
that recent studies have demonstrated that bulk collagen is a poor
predictor of disease progression in PDAC.16
Following this in vivo characterisation, polyacrylamide gels were
used to recapitulate the values of tissue rigidities observed in
healthy and diseased pancreas to determine the speciﬁc role of
matrix rigidity in promoting the malignant cell processes of EMT
and chemoresistance in pancreatic cancer cell lines. EMT is
characterised by particular changes of marker proteins and cell
morphology, which were observed to show gradual increases in
mesenchymal behaviour following culture on gels of increasing
rigidity, for multiple pancreatic cancer cell lines. The sensitivity of
EMT induction to matrix stiffness correlates to the original
phenotype of the cells. The highly epithelial cell line BxPC-3
shows the highest sensitivity, the highly mesenchymal cell line
Suit2-007 shows a lower responsiveness and the intermediate cell
line AsPC-1 shows an intermediate receptivity. The gradual nature
of the transition observed here conﬁrms its plasticity under these
in vitro conditions. In contrast, YAP, TAZ and β-catenin localisation
events occur within individual cells in a binary manner, and this
suggests that other mechanotransduction pathways, such as the
AKT or mitogen-activated protein kinase pathways that are known
to promote EMT in response to stiffness in other cancers,40 should
be investigated for further understanding of mechanosignalling
and EMT.
The ability of cancer cells to escape the cytotoxic effects of
therapeutics drugs is fundamental for cancer progression. Multiple
drugs are used in PDAC treatment with differing mechanisms of
action, and here we observe a marked dependence of the drug
mechanism of action in determining whether the stiffness
component of PDAC is responsible for inducing chemoresistive
properties. In vivo EMT is known to promote resistance to
gemcitabine, a nucleoside analogue that inhibits DNA synthesis
and transcription.54 Here we report that in vitro gemcitabine
resistance is unchanged with increased rigidity, despite also
observing that gel rigidity can promote elements of EMT.
Gemcitabine treatment is also seen to cause YAP/TAZ nuclear
localisation to a percentage seen for 25 kPa gels, likely due to
deregulation of the LATS1/2-mediated negative feedback loop56
by preventing transcription of LATS1/2. This would lead to
YAP/TAZ dephosphorylation and nuclear localisation but without
further EMT induction. This is corroborated by the observation
that vimentin expression on high stiffness gels reverts to a level as
seen on 1 kPa gels with 1 mM concentrations of the drug.
As gemcitabine is a nucleoside analogue that inhibits DNA
replication, it would also likely inhibit transcription and therefore
inhibit expression of mesenchymal markers and maintenance of
the phenotype.
Paclitaxel, a taxane that stabilises microtubules and therefore
prevents mitosis, has shown potential for PDAC treatment, as it is
one of the few drugs that has signiﬁcantly improved the survival
rates in patients when combined with nucleoside analogues,
such as gemcitabine or platinum derivatives.52 In contrast to
gemcitabine, cells grown on 4 and 25 kPa gels show increases in
resistance to paclitaxel compared with the 1 kPa conditions.
The 4 kPa condition therefore, representing PDAC stiffness, is
an intermediate stage in the transition that provides some
drug-resistive properties and in which cells with or without
YAP/TAZ nuclear localisation respond in a similar manner to the
presence of paclitaxel. Gemcitabine and an albumin-bound form
Figure 4. The role of matrix stiffness in gemcitabine and paclitaxel chemoresistance. (a) Dose–response curve for BxPC-3 cell viability with
increasing concentrations of gemcitabine. For 1, 4 and 25 kPa, respectively, total n= 81, 74, 65. Values represent mean± s.e.m. (b) IC50 values
from dose–response curves in panel (a). Values represent mean± s.e.m. (c) Normalised vimentin intensity (corrected cell total ﬂuorescence).
For 1, 4 and 25 kPa, respectively, for control conditions, n= 23,20,20. For 1, 4 and 25 kPa, respectively, for 1 mM gemcitabine conditions, n= 18,
13, 15. Values represent mean± s.e.m. *Po0.05, ***Po0.001. (d) Changes in population nuclear YAP percentage. For 1, 4 and 25 kPa,
respectively, total n= 76, 74, 78. Changes in population nuclear TAZ percentage. For 1, 4 and 25 kPa, respectively, total n= 72, 76, 68. Values
represent mean± s.e.m. (e) Dose–response curve for BxPC-3 cell viability with increasing concentrations of paclitaxel. For 1, 4 and 25 kPa,
respectively, total n= 58, 67, 54. Values represent mean± s.e.m. (f) IC50 values from dose–response curves in panel (e). Values represent
mean± s.e.m. (g) Normalised vimentin intensity (corrected cell total ﬂuorescence). For 1, 4 and 25 kPa, respectively, for control conditions,
n= 42, 39, 23. For 1, 4 and 25 kPa, respectively, for 1 mM gemcitabine conditions, n= 32, 20, 30. Values represent mean± s.e.m. **Po0.01,
***Po0.001. (h) Changes in population nuclear YAP percentage. For 1, 4 and 25 kPa, respectively, total n= 58, 56, 66. Changes in population
nuclear TAZ percentage. For 1, 4 and 25 kPa, respectively, total n= 77, 59, 65. Values represent mean± s.e.m.
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of paclitaxel have been shown in combination to promote overall
survival for patients with metastatic PDAC in a randomised phase
III trial,57 and their effectiveness may be due to the potent
combination of abrogation of the mesenchymal phenotype and
toxicity to epithelial cells. This is speculated to act in addition
to the known ability of paclitaxel to potentiate gemcitabine
toxicity in vivo by decreasing levels of cytidine deaminase,58
which dephosphorylates and thus inactivates gemcitabine.59
Though stiffness is seen here to induce paclitaxel resistance
in vitro, paclitaxel has been observed to decrease tumour
stiffness in vivo,53 and it is yet to be determined whether the
paclitaxel-resistant phenotype induced by stiffness can persist in a
lower stiffness environment.
The characterisation here of how stiffness promotes different
elements of EMT to different degrees, as shown in Figure 5, has
great relevance for clinical understanding of PDAC development.
Therapeutics that seek to the disrupt the mechanosensing of cells
within the tumour may beneﬁt from an understanding of the
speciﬁc role of stiffness in EMT induction and the possible role of
stiffness in combination with other variables associated with the
PDAC microenvironment. It is therefore vital for further studies to
be conducted that assess whether matrix stiffness can act
synergistically with other microenvironmental cues. For example,
the in vitro mesenchymal phenotype promoted by matrix rigidity
is seen here to be ineffective in gemcitabine resistance, whereas
the in vivo mesenchymal phenotype promotes resistance.11 This is
likely due to other in vivo factors inducing further elements of
EMT, perhaps a further induced transition to a more stable
mesenchymal state in which cells can prevent the action of
gemcitabine to a greater degree.
MATERIALS AND METHODS
Mouse tissues
Mouse tissues for healthy pancreas (Pdx-1-Cre), PanIN (Pdx1-Cre;
LSL-KrasG12D/+) and PDAC (Pdx1-Cre; LSL-KrasG12D/+ LSL-Trp53R127H/+) were
obtained from Dr Jennifer Morton at the Beatson Institute in Glasgow, UK
in the form of Optimal Cutting Temperature (OCT)-embedded tissues and
frozen tissue samples. All studies were conducted in compliance with the
UK Home Ofﬁce guidelines under license and approved by the local ethical
review committee.
Histology
OCT-embedded samples were sectioned with a cryostat. These formalin-
ﬁxed OCT-embedded 10 μm sections were stained with Sirius Red in picric
acid and viewed by brightﬁeld microscopy. Alignment analysis was carried
out on non-overlapping regions of 75 × 75 μm2 size as in Robinson et al.33
BoneJ analysis30 was used for ﬁbre thickness quantiﬁcation.
Atomic force microscopy
Stiffness was measured by AFM with a JPK Nanowizard-1 (JPK Instruments,
Berlin, Germany) in force spectroscopy mode, mounted on an inverted
optical microscope (IX-81; Olympus, Tokyo, Japan). For tissue samples,
glass beads of 35 μm radius were attached to pyramidal cantilevers (MLCT;
Bruker, Camarillo, CA, USA) with a spring constant of 0.07 N/m. For
polyacrylamide gel veriﬁcation, pyramidal cantilevers with spring constant
0.05 N/m and a half-angle to face of 17.5° were used. Sensitivity of the
cantilevers was calculated by analysing the gradient of the force–distance
curve in the AFM software (JPK Instruments) on the base of the petri dish.
Tissue samples thawed from frozen or polyacrylamide gels stored in
phosphate-buffered saline (PBS) were attached to the base of a petri dish
with a cyanoacrylate adhesive. For tissue samples, indentation tests for
tissue samples were carried out to generate 30 force curves across 6
regions of 100× 100 μm2 size, with an approach speed of 5 μm/s and a
maximum set force of 1 nN. Polyacrylamide gel veriﬁcation was performed
across multiple gels prepared independently, with 9 measurements within
a 100× 100 μm2 area, which was averaged to give each independent value
to be used in data representation and statistical analysis. The Young’s
modulus was calculated using the AFM software by ﬁtting the Hertz
contact model60 to the acquired force curves.
Polyacrylamide gels
Fresh 13 mm glass coverslips were activated by dipping in 0.1 M NaOH and
left to dry. (3-Aminopropyl) triethoxysilane 4.0% (Sigma-Aldrich, St Louis,
MO, USA) was used to coat the coverslips with an amine-reactive ﬁlm,
before washing in distilled water for 10 min. After drying, coverslips were
coated with 2.5% glutaraldehyde (Sigma-Aldrich) for 30 min, and then
washed twice in distilled water for 10 min, to produce a coating of
aldehyde functional groups. Polyacrylamide gels (500 μl) were made by
mixing PBS, acrylamide/bisacrylamide (29:1) 40% vol (Sigma-Aldrich) 1 μl
TEMED (Sigma-Aldrich) and 2.5 μl 10% ammonium persulphate. The
acrylamide/bisacrylamide volume for each gel was 34.9, 59.4 and
125.3 μl, known to produce gels of 1, 4 and 25 kPa stiffness, respectively.
In all, 10 μl of gel was applied to dichlorodimethylsilane (Sigma-Aldrich)
coated glass microscope slides and activated coverslips were placed on
top for 45–60 min. Coverslips were washed in PBS on the rocker for 20 min
and then sterilised in fresh PBS for 30 min with ultraviolet light. A total of
50 μl of the heterobifunctional sulphosuccinimidyl 6-(4′-azido-2′-nitrophe-
nylamino) hexanoate (sulpho-SANPAH) was added and photoactivated for
5 min with ultraviolet light. After washing with PBS, coverslips were coated
with 10 μl/ml ﬁbronectin solution for 1.5 h and washed before cell seeding.
If adrenaline or blebbistatin was to be used, cells were seeded in normal
media and left for 1–2 h to spread and attach, before changing the media
to drug-containing media.
Epithelial Intermediate
1 kPa 4 kPa 25 kPa
+ Paclitaxel Chemoresistance
Matrix Stiffness
2 kPa
Healthy
PanIN
PDAC
YAP/TAZ
Vimentin
F-actin
Mesenchymal
Figure 5. Diagram of stiffness-induced progression of the EMT. The proposed role of stiffness in promoting progression through EMT in
pancreatic cancer cells and its relevance to in vivo measurements of tissue stiffness with PDAC progression.
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Cell culture
BxPC-3 and Suit2-007 cells were obtained from Dr Silvia Ottaviani at
Hammersmith Hospital, London, UK. Both BxPC-3 and AsPC-1 cells
were grown in RPMI 1640 with 10% foetal bovine serum heat inactivated
(Gibco, Loughborough, UK), 2 mM L-glutamine, 1% penicillin/streptomycin
(Sigma-Aldrich) and 1 % fungizone Anphotocerin B (Gibco, UK). Suit2-007
cells were grown in Dulbecco’s modiﬁed Eagle’s medium with the same
supplements added. All cells were tested for mycoplasma contamination.
Chemoresistance
To assay chemoresistance, cells were seeded on polyacrylamide gels and
left to grow for 72 h. After this, media was changed for media with the
relevant concentration of gemcitabine hydrochloride (Sigma-Aldrich) or
paclitaxel (Sigma-Aldrich) and left for 72 h. Gels were washed with PBS and
incubated with 70 μl MTS reagent (Promega, Madison, WI, USA) and 350 μl
of clear RPMI media (Gibco, UK) for 1 h. The solution in each well was split
into three wells of a 96-well plate and absorbance was read at 490 nm with
a Tecan plate reader (Tecan, Grödig, Austria).
Cell ﬁxation and staining
Cells on coverslips were ﬁxed 72 h after seeding unless otherwise
speciﬁed, using 4% paraformaldehyde in PBS for 30 min at 37 °C. For
staining, cells were permeabilised and blocked with 2% bovine serum
albumin/0.1% Triton-X in PBS for 10 min and then stained with primary
antibody diluted in 2% bovine serum albumin in PBS for 1 h. After a PBS
wash, cells were stained with the relevant secondary antibody (1/500) and
phalloidin (1/500) in PBS. Following a further PBS wash, coverslips were
mounted in ProLong Gold Antifade with DAPI (4,6-diamidino-2-phenylin-
dole; ThermoFisher Scientiﬁc, Eugene, OR, USA). Images were taken with a
Nikon Eclipse Ti-E microscope (Nikon, Kingston-upon-Thames, UK) at × 20/
×40 magniﬁcation.
Antibodies used were the following: vimentin (Dako M075, Carpinteria,
CA, USA), E-cadherin (Santa Cruz sc-21791), β-catenin (Santa Cruz sc-7199,
Dallas, TX, USA), YAP (Santa Cruz sc-101199), TAZ (Abcam ab84927,
Cambridge, UK), Phalloidin (Life Technologies A22283, Eugene, OR, USA),
AlexaFluor 488 goat anti-rabbit IgG (Life Technologies A11034), AlexaFluor
goat anti-mouse IgG (Life Technologies A11029), Goat antibody to rabbit
IgG (horseradish peroxidase (HRP)) (Abcam ab6721), and HRP Goat Anti-
Mouse IgG (Life Technologies 626520).
Image analysis
Alignment analysis on collagen images was conducted as described
previously for 75 × 75 μm2 regions.33 Nuclear localisation of β-catenin, YAP
and TAZ was calculated as how many cells at × 20 magniﬁcation showed
staining for the relevant antibody within the nuclear region, as delineated
by staining with DAPI. Vimentin and F-actin intensity were determined by
corrected total cell ﬂuorescence in ImageJ (NIH, MD, USA), as calculated by
Intensity density -Mean intensity of background
Cell area , to assess only the ﬂuorescence due to
cell-speciﬁc staining. Roundness was calculated as a product of the
variance of the radius of a given cell, for 360 radii taken at 1° angles, using
a custom-built code. Clustering scores were determined by inspection of
images with phalloidin staining, with the non-clustering percentage
calculated as the percentage of cells that did not form any cell–cell
junctions.
Western blottings
Cell lysates from cells grown on polyacrylamide gels of different rigidities
were prepared with radio immunoprecipitation assay buffer (Sigma, R0728,
Berlin, Germany) with protease and phosphatase inhibitors (Sigma P4340).
Protein quantiﬁcation was determined with the DC Protein Assay (Bio-Rad,
500-0113, Hercules, CA, USA) according to the instructions provided.
Sodium dodecyl sulphate–polyacrylamide gel electrophoresis was used to
separate samples under reducing conditions and were transferred to a
polyvinylidene diﬂuoride membrane (Protran BA85, Berlin, Germany) and
blocked with 5% bovine serum albumin (Sigma, A8022) in TBST (TBS with
0.1% Tween-20 (Sigma, P1379)). Primary antibodies were prepared in this
blocking solution and membranes were incubated overnight at 4 °C. The
membrane was washed in TBST and incubated with HRP-conjugated
secondary antibodies in TBST for 1 h at room temperature. The membrane
was washed and developed with the HRP substrate (Millipore, WBLUR0100,
Billerica, MA, USA).
Reverse transcriptase–PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, 74104, Hilden,
Germany) and 1 mg of total RNA was reverse-transcribed using the High-
Capacity RNA-to-cDNA Kit (Applied Biosystems, 4387406, Loughborough,
UK) according to the manufacturer’s instructions. Quantitative PCR was
performed using the SYBR Green PCR Master Mix (Applied Biosystems,
4309155) with 100 ng cDNA input in 20 ml reaction volume. GAPDH
(glyceraldehyde 3-phosphate dehydrogenase) expression level was used
for normalisation as a housekeeping gene. The sequences were as
following: vimentin: forward-5′-GGAAACTAATCTGGATTCA-3′, reverse-5′-
CATCTCTAGTTTCAACCGTC-3′; E-cadherin: forward-5′-CCGAGAGCTACACG-
TTC-3′, reverse-5′-TCTTCAAAATTCACTCTGCC-3′; CTGF: forward-5′-TTAAGA-
AGGGCAAAAAGTGC-3′, reverse-5′-CATACTCCACAGAATTTAGCTC-3′; ANKDR1:
forward, 5′-TGAGTATAAACGGACAGCTC-3′ and reverse, 5′-TATCACGGAATTC-
GATCTGG-3′; and GAPDH: forward-5′-ACAGTTGCCATGTAGACC-3′, reverse-5′-
TTTTTGGTTGAGCACAGG-3′. All primers were used at 300 nM ﬁnal concentra-
tion. The relative gene expression was analysed by comparative 2−ΔΔct
method.
Statistics
Unless otherwise speciﬁed, statistical analysis was conducted as an
unpaired Mann–Whitney test (two-tailed). All statistical tests where a
normal distribution was assumed had no signiﬁcant differences in
variance.
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